The Beneficial Role of Probiotic Lactobacillus in Respiratory Diseases

Tingfeng Du, Aihua Lei, Naiyu Zhang and Cuiming Zhu*

Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hengyang, China

Respiratory diseases cause a high incidence and mortality worldwide. As a natural immunobiotic, Lactobacillus has excellent immunomodulatory ability. Administration of some Lactobacillus species can alleviate the symptoms of respiratory diseases such as respiratory tract infections, asthma, lung cancer and cystic fibrosis in animal studies and clinical trials. The beneficial effect of Lactobacillus on the respiratory tract is strain dependent. Moreover, the efficacy of Lactobacillus may be affected by many factors, such as bacteria dose, timing and host background. Here, we summarized the beneficial effect of administered Lactobacillus on common respiratory diseases with a focus on the mechanism and safety of Lactobacillus in regulating respiratory immunity.

Keywords: Lactobacillus, respiratory diseases, the gut-lung axis, mucosal immunity, safety

1 INTRODUCTION

Probiotics are defined as “live microorganisms” and confer a health benefit on the host when properly administered (1). Many probiotics have been shown the beneficial properties, including Lactobacillus spp., Bifidobacterium spp., Enterococcus spp., Streptococcus spp., Propionibacterium spp., Bacillus cereus, Saccharomyces boulardii, and several specific strains of Escherichia coli (1, 2). Among probiotics, the most widely used are microorganisms of the genus Lactobacillus, which contains more than 200 species bacteria (3, 4). Lactobacillus spp. are gram-positive, facultative anaerobic bacterium that ferments carbohydrates to produce lactic acid (5), and has a high economic value due to the use in biotechnology, food as well as therapeutic application (4, 6, 7).

In human hosts, Lactobacillus spp. exist in the gastrointestinal tract, vagina, oral cavity, respiratory tract and skin. They account for 6% and 95% of the total bacteria in the intestinal and vaginal tracts, respectively (8).

As natural immunobiotics, Lactobacilli have excellent immunomodulatory function, and their ability in improving gastrointestinal, oral and vaginal disorders is already well known (6, 9–12). Meanwhile, emerging evidence shows that Lactobacillus can also modulate respiratory immunity (13–16). Administration of Lactobacillus confer a beneficial role in respiratory diseases including respiratory tract infections (RTIs), asthma, lung cancer, cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) (17–21). Administration of Lactobacillus may be an alternative strategy...
to alleviate respiratory diseases. In this review, we focus on the beneficial effect of probiotic Lactobacillus in promoting respiratory health and discuss its potential mechanism and safety.

### 2 BENEFICIAL ROLE OF LACTOBACILLUS IN RESPIRATORY DISEASES

#### 2.1 Respiratory Tract Infections

RTIs are the major source of incidence and mortality in the world (22). Although many RTIs are of mild and self-limited nature, they caused 4 million deaths worldwide each year (23, 24). In 2017, influenza virus has infected 54.5 million people worldwide, resulting in about 145,000 deaths (25). Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is raging globally. Effective vaccines are not available for many respiratory pathogens, and the increase in drug-resistant microbe makes the effective treatment of RTIs extremely challenging. Therefore, it is important to find a safe and effective method to reduce the risk of RTIs. Recently, the probiotic Lactobacillus has been used to fight against a variety of RTIs, including virus and bacterial infection (Table 1). Oral administration of Lactobacillus can improve symptoms caused by poly(I:C) treatment (49). Many Lactobacillus species can prevent influenza virus infection, including L. rhamnosus GG, L. casei Shirota, L. plantarum DK119, L. paracasei MCC1849, L. gasseri SBT2055, L. fermentum CJ1-112 and L. kunkeei YB38 (34, 50–55). Moreover, Lactobacilli also have excellent role as a vaccine or adjuvant in preventing influenza virus infection due to its safety and biotechnological advantage (56–58). It is worth pointing out that oral supplementation with L. johnsonii (strain not shown) in pregnant BALB/c mice can reduce Th2 type cytokines and lung inflammation in Respiratory Syncytial Virus (RSV)-infected newborn mice (59). It means Lactobacillus may have preventive effect for RTIs of offspring when administered to the mother. Notably, supplementation with live and inactivated bacteria of the same Lactobacillus strain (such as L. rhamnosus CRL1505) generally have similar effect (39, 40), suggesting that viability is not necessary for Lactobacillus to achieve the protective immunoregulatory effect. However, nasally administered viable but not heat-killed L. rhamnosus CRL1506 can provide complete protection against RSV infection in mice (28). Although the reason needs further investigation, it shows that Lactobacilli efficacy is strain-dependent. Therefore, the selection of a Lactobacillus strain with potent immunomodulatory ability is crucial.

Although vaccines for SARS-CoV-2 are available, the rapidly SARS-CoV-2 mutating makes the effectiveness of these vaccines challenging (60). Notably, in vitro experiment has demonstrated that L. fermentum 90 TC-4 pretreatment increases the activity of SARS-CoV-2-infected Vero E6 cells (grass monkey kidney cells) (61). Pretreatment of L. plantarum MPL16 and CRL1506 can also inhibit the proliferation of SARS-CoV-2 in human lung epithelial cell line Calu-3 (62). In Central Europe, it has been reported that low death rate of COVID-19 patients is associated with the consumption of fermented vegetables containing many Lactobacilli species (63). Therefore, Lactobacilli may have the potential to become an adjuvant for treating SARS-CoV-2.

However, there are some limitations in the therapeutic effect of administering Lactobacillus. For example, neonatal C57BL/6 mice pre-treated with L. rhamnosus GG maintain 100% survival rate post influenza virus infection; however, the survival rate is only 10% when mice treated with L. rhamnosus GG at 48h post influenza virus infection (29). Similarly, the survival rate of BALB/c mice treated with L. plantarum at 24h post Pneumonia virus infection is 100%, but all mice die when L. plantarum administered at 72h post infection (3, 64). These results show that Lactobacillus administration post infection cannot exert an obvious protective immunoregulatory effect.

Lactobacilli can also provide resistance to respiratory bacterial infections. Administration of Lactobacilli such as L. rhamnosus CRL1505, L. casei CRL 431 and L. pentosus B240 increases resistance of mice to Streptococcus pneumoniae infection (41–43). Intranasal inoculation of L. rhamnosus CRL1505 is beneficial in S. pneumoniae infected-immunodeficient mice (39). Interestingly, peptidoglycan from L. rhamnosus CRL1505 shows a similar protective effect with the whole bacteria in preventing S. pneumoniae infection (40). Moreover, nasal administration of L. rhamnosus CRL1505 can also reduce pathogen load and lung damage of infant mice with RSV infection and secondary S. pneumoniae infection (65, 66).

In clinical trials, Lactobacilli are generally given in the form of tablets, capsules, powders, fermented yogurt or dairy products, and mainly used for preventive purposes (Table 2). For instance, oral L. rhamnosus GG in adults can reduce rhinovirus infection (83), and the combination of oral L. paracasei (strain not shown), L. casei CRL 431 and L. fermentum PCC also reduces rhinovirus-induced common and influenza-like infection (78). In addition, oral mixed probiotic (mainly Lactobacilli) can decrease the risk of respiratory failure in COVID-19 patients by 8-fold and reduce the rate of transfer to Intensive Care Unit and mortality (84). In patients with severe COVID-19, oral tablet (live B. longum, live L. bulgaricus and live S. thermophilus, strains not shown) also shortens the time to reach a negative nucleic acid test of SARS-CoV-2 and decreases blood C-reactive protein and procalcitonin (81). Moreover, clinically administration of many Lactobacillus species such as L. rhamnosus GG, L. paracasei N1115 and L. plantarum L-137 can decrease the total incidence as well as shorten the duration of RTIs (26, 27, 81). Therefore, the prospect of Lactobacillus clinical application in reducing the risk of RTIs is promising.

#### 2.2 Asthma

Asthma is a heterogeneous airway disease, which behaves as complex symptoms, including cough, intermittent wheezing, dyspnea, chest tightness, airway obstruction, and bronchial hyperresponsiveness. Asthma patients generally have a Th1/Th2 imbalance and are polarized toward Th2 type immune response, usually resulting in high level of allergen-specific IgE and eosinophilic airway inflammation (85). Although asthma can be treated by strategies include allergen avoidance and improvement of signs and symptoms by inhaled corticosteroids, anti-leukotrienes...
TABLE 1  | Pre-clinical studies on the administration of the Lactobacillus for protection against bacterial and viral respiratory tract infections.

| Lactobacillus strain | Pathogen | Dose and route of administration | Experimental model | Benefits | References |
|----------------------|----------|----------------------------------|--------------------|----------|------------|
| *L. rhamnosus* CRL1505 and *L. johnsonii* | Respiratory syncytial virus | 1 × 10^8 CFU viable *L. rhamnosus* CRL1505, via oral | Infant BALB/c mice | Pulmonary viral load and injury are reduced | (26, 27) |
|  |  | 1 × 10^7 CFU viable *L. johnsonii*, via intranasal |  |  |  |
|  |  | 1 × 10^7 CFU L. rhamnosus CRL1505 or *L. rhamnosus* CRL1506, via intranasal | Female 3-week-old BALB/c mice | Pulmonary viral load and injury are reduced | (28) |
|  |  | 1 × 10^9 CFU L. rhamnosus CRL1505 or *L. rhamnosus* CRL1506, via intranasal |  |  |  |
| *L. rhamnosus* CRL1505 and *L. rhamnosus* CRL1506 | Viral pathogen molecular pattern poly[I:C] + Respiratory syncytial virus | 200 µg heat-killed L. casei Shirota, via intranasal | SPF female BALB/c mice | Improvement in survival rate and reduction in lung viral load, pulmonary inflammation was reduced | (3) |
|  |  | 200 µg heat-killed L. casei Shirota, via intranasal |  |  |  |
|  |  | 20 mg Lyophilized L. plantarum 06CC2 powder, via oral |  |  |  |
| *L. rhamnosus* CRL1505 and *L. johnsonii* | Pneumonia virus | 1 × 10^7 CFU viable L. johnsonii CRL1505, via intranasal | Wild-type BALB/c and C57BL/6 mice | Improvement in survival rate and reduction in lung viral load, pulmonary inflammation was reduced | (3) |
|  |  | 1 × 10^7 CFU viable L. johnsonii CRL1505, via intranasal |  |  |  |
|  |  | 1 × 10^8 CFU L. rhamnosus CRL1505 or *L. rhamnosus* CRL1506, via intranasal |  |  |  |
| *L. casei* Shirota and *L. paracasei* ST11 | Influenza A/H11N1 virus PR8 | 2 × 10^6 CFU viable L. paracasei CIRM653 (45, 46) | Six-week-old female BALB/c mice | Weight loss is suppressed, pulmonary viral load is reduced | (36) |
|  |  | 2 × 10^6 CFU viable L. paracasei CNCM I-1518, via oral |  |  |  |
|  |  | 1.5 × 10^8 CFU viable L. paracasei CNCM I-1518, via oral |  |  |  |
| *L. casei* CRL 431 | Influenza A/H9N2 virus | 200 µg heat-killed L. casei CRL 431, via oral | Six-week-old female BALB/c mice | Improvement in survival rate and reduction in lung viral load, pulmonary inflammation was reduced | (37) |
|  |  | 100 mg/kg heat-killed L. casei CRL 431, via oral |  |  |  |
| *L. paracasei* ST11 | Vaccinia virus | 1 × 10^8 CFU viable L. paracasei ST11, via oral | BALB/c mice (6-week-old females) | Weight loss is suppressed and pulmonary viral load is reduced | (35) |
| *L. rhamnosus* CRL1505 and *L. gasseri* TMC0356 | Streptococcus pneumoniae | 1 × 10^8 CFU viable or non-viable L. rhamnosus CRL1505, via intranasal | Immunedeficient Swiss- albinino mice | Lung load of pathogens and injury are reduced | (39–41) |
|  |  | 1 × 10^8 CFU viable or non-viable L. rhamnosus CRL1505, via intranasal |  |  |  |
| *L. pentosus* t240 and *L. casei* CRL 431 | S. pneumoniae | 500 mg kg⁻¹ heat-killed L. pentosus t240, via oral | Five-week-old male mice | Prolonged survival time, less body weight loss and lung viral load | (42) |
|  |  | 1 × 10^8 CFU viable L. casei CRL 431, via oral or via intranasal | Adult 8-week-old Swiss albinino mice and immunodeficient Swiss- albinino mice | Lung bacterial load is decreased and lung inflammation is reduced, accelerated weight recovery | (43, 44) |
| *L. casei* CRL 431 and LLG | Pseudomonas aeruginosa | 1 × 10^8 CFU viable L. casei CRL 431, via oral or via intranasal | Three-week-old mice (young mice) | Bacterial clearance of lung tissue is increased | (45, 46) |
|  |  | 1 × 10^8 CFU viable *L. casei* CRL 431, via oral or via intranasal |  |  |  |
| *L. plantarum* CIRM653 | Klebsiella pneumoniae | 1 × 10^8 CFU viable L. plantarum CIRM653, via oral | 6-8-week-old C57/BL6J mice | The pulmonary inflammation response is reduced | (47) |
|  |  | 1 × 10^8 CFU viable L. plantarum CIRM653, via oral |  |  |  |
| *L. murinus* CNCM I-5314 | Mycobacterium tuberculosis (H37Rv) | 1 × 10^7 CFU viable L. murinus, via oral | Six-eight-week-old female SPF C57/BL6 mice | Reduction in pulmonary inflammation | (48) |

References:

(26, 27) Du et al. (2022). Frontiers in Immunology, 13, 9080103.
and β2 agonists, there is still no specific treatment for asthma and healthcare is expensive during exacerbation (86). Emerging evidence suggests that respiratory asthma symptoms can be ameliorated when probiotic Lactobacillus is administered. Oral administration of many Lactobacillus species has shown an effective preventive role for asthma in animal studies, including L. rhamnosus GG, L. plantarum K37, L. reuteri (ATCC No. 23272), L. casei Shirota, L. paracasei HB89 and L. salivarius (strain not shown) (18, 87–91). Some Lactobacillus species such as L. rhamnosus GG, L. paracasei (strain not shown) and L. fermentum (strain not shown) are orally used in the clinical and have beneficial effect on asthma in children (92, 93). Interestingly, the acute asthma is closely associated with RTIs, especially rhinovirus infection (94). Consequently, the role of Lactobacillus administration in preventing RTIs may be useful in relieving exacerbation of acute asthma. Based on the "hygiene hypothesis," exposure to specific microbial components early in life can decrease the susceptibility to asthma and allergic diseases (95). Therefore, oral administration of probiotic Lactobacillus in the early life may also play an important role in preventing asthma.

For the purpose of asthma prevention, the general route of administration of Lactobacillus species is oral delivery. However, a study indicates that although oral administration of L. paracasei NCC2461 could provide effective protection for female BALB/c mice with asthma, the efficacy of intranasal delivery is better (96). Nevertheless, two studies show that oral administration of L. rhamnosus GR-1 prevents the worsening of asthma in male BALB/c mice, but nasal administration has little effect on the improvement of asthma symptoms in male BALB/c mice (97, 98). This may be caused by the lower dose and duration of nasal administration. Interestingly, oral administration of L. paracasei NCC2461 in perinatal mice provides prevention for allergic airway inflammation in the offspring (99). Similarly, in clinical trials, oral L. rhamnosus GG has been shown to prevent atopic diseases in children in both prenatal and postnatal (100). Thus, Lactobacillus may have a preventive effect against offspring asthma when administered to the mother. Furthermore, supplementation with Lactobacillus GG also has a therapeutic rather than only a preventive effect on mice suffering from asthma (101). Additionally, animal studies have found that oral Lactobacillus can also reduce other airway allergic reactions such as allergic rhinitis. For example, oral L. rhamnosus GG, L. gasseri TMC0356, L. plantarum IM76, L. plantarum CJLP133 and CJLP243 can effectively improve the symptoms of allergic rhinitis (102–104). In clinical trials. L. gasseri KS-13, L. casei Shirota and L. acidophilus L-92 have been used to effectively prevent seasonal allergic rhinitis (105–107). Thus, the administration of Lactobacillus may have excellent preventive effect on airway allergic reaction.

### 2.3 Lung Cancer

Lung cancer is a malignant tumor with a high incidence and mortality rate in the world (108). In recent years, immunotherapy has sparked a new surge in tumor treatment. Although immune

| Lactobacillus strain | Subjects | Efficacy | References |
|----------------------|----------|----------|------------|
| L. rhamnosus GG      | Premature infants | The reduction in the incidence of RTIs | (67) |
| L. casei Shirota     | Healthy middle-aged working people | Reducing the incidence and duration of upper respiratory tract infections (URTIs) | (68) |
| L. casei DN 114001   | Healthy school-age children | The reduction in the incidence and duration of RTIs | (69) |
| L. reuteri SD 112    | Infants | Reducing the rate and duration of RTIs | (70) |
| L. plantarum L-137   | Healthy subjects with high psychological stress | The reduction in the incidence of URTIs | (71) |
| L. plantarum DR7     | Adults | Improving clinical symptoms of URTIs | (14) |
| L. paracasei N1115   | Older Adults | Strengthening resistance of RTIs | (72) |
| L. fermentum CECT5716 | Infants | Reducing the incidence of URTIs | (73) |
| L. fermentum PCC     | Athletes | The reduction in lower respiratory symptoms in men | (74) |
| L. salivarius        | Athletes | No effect on the frequency of URTIs | (75) |
| L. helveticus Lafti L10 | Athletes | Shortening the duration of RTIs | (76) |
| Combination of L. rhamnosus GG, L. rhamnosus LG705, B. breve 99, P. freudenreichii JS | Children | Reducing the incidence of RTIs | (77) |
| Combination of L. paracasei, L. casei 431, L. fermentum POC | Adults | Strengthening resistance of common cold and flu-like respiratory infections | (78) |
| Combination of L. acidophilus, B. lactis UABLA-12 | Children | Do not reduce the incidence, but shorten the duration of acute respiratory infections | (79) |
| Combination of L. gasseri PA16/8, B. longum SP07/3 | Adults | Reducing the duration of RTI episodes and fevers | (80) |
| Combination of B. longum, L. bulgaricus and S. thermophilus | Patients with COVID-19 | The duration of diarrhea is shortened. Significantly shorter time to nucleic acid negativity and significantly lower inflammatory markers such as calcitoninogen and C-reactive protein | (81) |
| Combination of L. plantarum KABP022, KABP023, KABP033, and P. acidilactici KABP021 | Patients with COVID-19 | The reduction in nasopharyngeal viral load, pulmonary infiltration, and duration of digestive and non-digestive symptoms. | (82) |
check inhibitors (ICIs) such as anti-PD-1/PD-L1 and anti-CTLA 4 antibodies has become the first-line clinical treatment for tumors, the application of ICIs increases T-cell activity and removes the “braking” of the immune system, and these drugs are likely been associated with immune-related adverse events, especially when used in combination (109). Therefore, the search for natural immunobiotics with immunomodulatory properties to assist in the treatment of cancer patients may be a direction. It has been reported that probiotics show the same degree of anti-tumor ability as PD-L1 inhibitors, while simultaneous combination therapy with PD-L1 inhibitors virtually eliminated tumor growth in mice (110). Moreover, in clinical trials, oral administration of yogurt with probiotics provides a potential protective effect against lung cancer (111). *Lactobacillus* is one of the most widely studied probiotic involved in the treatment of lung cancer. Administration of *Lactobacillus* can inhibit the metastasis of tumor cells to the lung. For example, nasal administration of *L. rhamnosus* GG can inhibit the metastasis of melanoma B16 to the lung in C57BL/6 mice (112). *L. casei* (strain not shown) has significant inhibitory effect on the proliferation of A549 lung cancer cells *in vitro* (113). Furthermore, intravenous and intradermal injection of *L. casei* YIT 9018 can increase the anti-tumor activity against Lewis lung carcinoma in C57BL/6 mice (114). In addition, oral administration of *L. casei* CRL 431 also reduces the side effects of chemotherapy (115), which may improve the prognosis of lung cancer patients. These suggest that some *Lactobacillus* species may have potential to become an effective adjuvant to treat lung cancer.

### 2.4 CF

CF is an autosomal recessive, monogenic disease with lesions affecting the lung, intestine, and other organ, but lung disease is the leading cause of morbidity and mortality in people with CF (116). CF is closely related to intestinal flora and significantly reduces intestinal flora diversity (117, 118). A study indicates that oral *L. rhamnosus* GG improves disorders of intestinal flora in children with CF (119). Moreover, clinical trial shows oral administration of *L. rhamnosus* GG reduces pulmonary exacerbation and hospitalization rate in CF patients (120). This suggests administration of *L. rhamnosus* GG may be able to alleviate the symptoms of CF. In another clinical trial, however, oral administration of *L. rhamnosus* GG did not promote respiratory health in patients of CF (121). The main reason may be due to different inclusion criteria for clinical trial subjects. The clinical efficacy of applying a single *Lactobacillus* strain on CF is unstable, and the combined administration of multiple probiotic *Lactobacillus* species may be more effective. For example, intestinal supplementation with probiotic capsules (consisting mainly of *Lactobacillus* species) significantly reduces the incidence of lung deterioration and improves the quality of life in patients with CF (19, 122). However, these are single-center clinical trials. Multicenter and expansion of the number of subjects are needed to further clarify the efficacy of *Lactobacillus* administration on CF in clinical trials.

### 2.5 Other Respiratory Diseases

Several studies have reported the potential of *Lactobacillus* in improving COPD. The commonly known causes of COPD are cigarettes and air pollutants (123). *In vitro* experiment has demonstrated that *L. rhamnosus* NutRes1 can reduce inflammatory mediators produced by cigarette-activated human macrophages (124). Moreover, oral feeding of *L. rhamnosus* (strain not shown) increases levels of IL-10 as well as SOCS3 and TIMP1/2, and attenuates lung injury of COPD induced by cigarette in C57BL/6 mice (21). Additionally, the development of COPD is associated with reduction of *Lactobacillus* spp. in lung (125).

In addition, a study indicates that a decrease in intestinal *Lactobacillus* may contribute to the development of pulmonary arterial hypertension (126). In clinical trial, intestinal supplementation with *L. casei* Shirota can reduce the incidence of Ventilator-Associated Pneumonia in hospitalized patients (127). Thus, *Lactobacillus* may also be beneficial in other respiratory diseases and need more studies.

### 3 POTENTIAL MECHANISM OF PROBIOTIC LACTOBACILLUS IN IMPROVING RESPIRATORY DISEASES

As mentioned above, many members of the genus *Lactobacillus* have immunomodulatory properties. Notably, not only the whole bacteria, but also their components can exert immunomodulatory function, including peptidoglycans, extracellular polysaccharides, surface proteins and metabolites (short-chain fatty acids, SCFAs) and inorganic polyphosphates liquids (40, 128–131). The mechanism of health-promoting effect of *Lactobacillus* on respiratory tract is complex. The same bacteria, when administered orally or nasally, or even administered live and inactivated bacteria, may not have the same effect on promoting respiratory health (49, 50, 52). The potential mechanisms include gut-lung axis and enhancement of the local mucosal immunity of the respiratory tract.

### 3.1 The Gut-Lung Axis

In recent years, many studies have reported that there is a crosstalk between gut and lung, and this connection described as gut-lung axis seems to be bidirectional (132, 133). Oral administration of some probiotics, especially *Lactobacillus*, could promote respiratory health via gut-lung axis (17, 30, 134). Although the exact mechanisms by which *Lactobacillus enterica* affects the lung immunity via gut-lung axis are not fully understood, there are three main aspects (Figure 1).

#### 3.1.1 Direct Immigration of Immune Cells and Cytokines From the Intestine to the Respiratory Tract Through the Circulation

Recognition of *Lactobacillus* species or their components by pattern recognition receptors (PRRs, such as TLRs or NLRs, etc.) on immune cells in the intestinal mucosa can result in the
activation of innate immune cells which could migrate to lung tissue via circulation. For instance, innate lymphoid group 3 cells (ILC3s) can migrate from the gut to the lung where IL-22+ILC3 exhibits resistance to pneumonia (135). Oral delivery of L. paracasei CNCM I-1518 also significantly increases ILC3 in lung tissue and enhances resistance to influenza virus (36). Intestinal supplements with L. paracasei MCC1849 can provide protection against influenza virus, which may be associated with an increased proportion of IgA+ B cells and follicular helper T cells in Peyer’s patches and significantly increases IgA secretion in lung (53). Villena suggests that Oral delivery of L. rhamnosus CRL1505 induces Th1 response in the gut-associated lymphoid tissue and promotes the migration of Th1 cell to the lung tissue where Th1 cells produces IFN-γ which induces activation of alveolar macrophages, natural killer cells, CD103+ and CD11bhigh dendritic cell (DC) (49). Additionally, a study indicates that intestinal supplementation with L. rhamnosus GG can inhibit pulmonary inflammation, which is associated with an increase in Tregs of the intestinal tract (136). Moreover, oral administration of L. murinus (strain not shown) to antibiotic-treated mice can also increase Tregs in lung (137). Tregs not only inhibit inflammation, but also inhibit Th2 type immune response (138). As controlling airway inflammation is crucial in preventing asthma progression (94), migration of Tregs to lung tissue may alleviate asthma symptoms.

Cytokines secreted in the mucosa of the gastrointestinal tract by Lactobacillus can reach the circulation and interact with other mucosal tissues, such as lung (139). Intestinal supplementation with L. rhamnosus CRL1505 can increase TNF-α, IFN-α, IFN-β, IFN-γ in bronchoalveolar lavage fluid which exert a significant antiviral effect in the respiratory tract, and these cytokines show a similar increased trend in the intestinal fluid (49).

3.1.2 Influence of Lactobacillus Metabolites on Pulmonary Immunity via the Circulation

In parallel to promoting the migration of intestinal immune cells and cytokines, members of Lactobacillus genus produce metabolites that can modulate host respiratory immunity. The most important intestinal bacteria metabolites affecting pulmonary immunity is SCFAs, such as propionate, butyrate and acetate (140). Studies show that intestinal supplementation with many Lactobacillus species can increase SCFAs in the intestine and blood (141–145). The unmetabolized SCFAs enter the circulation and may affect pulmonary immunity in two ways. The first way is that SCFAs enter the bone marrow through the circulation enhancing generation of macrophage and DC progenitors (MDPs) (146), and meanwhile SCFAs can increase the conversion of MDPs into Ly6Cmonocytes (147, 148); then bone marrow Ly6Cmonocytes migrate into lung tissue where they differentiate into alternatively activated macrophages (149). The second way is that SCFAs directly enter into the lung tissue where they may activate G protein-coupled receptors (GPCRs) or inhibit histone deacetylase (150–152). For example, butyrate can not only promote the generation of Tregs and IL-10 production by activating GPR109A (153), but also restore IL-10 in the lung by inhibiting histone deacetylase in mice (154). Another metabolite of Lactobacillus enterica, lithocholic acid, can also enhance Tregs function while inhibit

![FIGURE 1](image-url) | Potential mechanisms of Lactobacillus to modulate respiratory immunity via the gut-lung axis (1). Migration of activated immune cells and cytokines from mesenteric lymph nodes (MLNs) and intestinal lamina propria to the lung through the circulation (2). Some endocrine cytokines (such as TNF-α, IL-8) may migrate to the lung tissue through the circulation, and then alter immune environment of the lung (3). SCFAs affect bone marrow hematopoiesis and promote the conversion of macrophage and DC progenitors (MDPs) into Ly6Cmonocytes, which reaches lung tissue and differentiates into anti-inflammatory alternatively activated macrophages (AAMs); AAMs inhibit chemokine CXCL1 production thus leading to reduced neutrophils recruitment in lung tissue (4). In the intestinal lumen, Lactobacillus or their components and production of metabolites (such as SCFAs) are taken up by intestinal epithelial cells and then enter to the lung via the circulation (5). Lactobacillus or their components from the intestinal lumen reach lung directly via microbreathing or esophageal reflux.
Th17 response (155). Other *Lactobacillus* intestinal metabolites (such as lactic acids, polyamines and indole derivatives) with immunomodulatory properties are involved in intestinal homeostasis (156–158). Nevertheless, it remains to be studied whether these metabolites can impact respiratory health via the gut-lung axis. In summary, *Lactobacillus* metabolites, such as SCFAs (especially butyrate) and lithocholic acid have excellent anti-inflammatory capacity, which may contribute to alleviate the development of RTIs, asthma, COPD. In addition to anti-inflammatory effect, butyrate and propionate can induce apoptosis of lung cancer cells and inhibit proliferation of lung cancer cells in vitro (159–161). Therefore, oral administration of some *lactobacilli* may provide benefit for the treatment of lung cancer by producing butyrate and propionate.

### 3.1.3 Migration of *Lactobacillus* and Their Components to the Lung

There may be two main routes for transfer of intestinal bacteria to the lung tissue: the first is intestinal bacteria or bacterial components enter into the circulation through the mesenteric lymphatic system and then reach the lung tissue (162–164); the second is the migration of intestinal bacteria or bacterial components to the lung tissue through microbreathing and oropharyngeal reflux (165, 166). Therefore, *Lactobacillus* or components of *Lactobacillus* in the intestine may be directly transferred to lung tissue and thus modulate lung immunity.

### 3.2 Enhancement of the Mucosal Immunity of the Respiratory Tract

Intestinal supplementation with *Lactobacillus* has been shown to promote respiratory health, but direct action of immunobiotic *Lactobacillus* on the respiratory mucosa may modulate local immunity of the respiratory tract. It has been found that intranasal administration of *Lactobacillus* can induce better respiratory immune response than oral administration (3, 50, 167). Nasal administration of *Lactobacillus* does not generally produce SCFAs due to the absence of substrate. The potential mechanisms by which they regulate respiratory immunity mainly have two aspects.

The first one is that some components of *Lactobacillus* can be recognized by PRRs in the respiratory tract and then activate downstream pathways. For example, nasal priming with peptidoglycan from *L. rhamnosus* CRL1505 increases TNF-α and IL-10 levels of lung and upregulates TLR2 and TLR9 expression in alveolar macrophages, which is similar to intranasal administration of whole bacteria (40). Meanwhile, other studies have shown that nasal priming with peptidoglycan from *L. rhamnosus* CRL1505 can enhance the TLR3/RIG-I-triggered antiviral immune response by increasing IFN-γ and NK cell activity, thus contributing to higher viral clearance and reducing lung tissue damage (28, 65, 168). In addition, lung peptidoglycan can also be recognized by peptidoglycan recognition proteins (PGRPs), a type of PRRs, which mediates bactericidal effect (169). For instance, activated PGRP2 could promote neutrophil recruitment in lung tissue of *S. pneumoniae* infected mice (170). Of note, not all peptidoglycan of *Lactobacillus* species has the same protective effect. Nasal administration the peptidoglycan from *L. rhamnosus* CRL534 does not enhance resistance to *S. pneumoniae* infection in immunodeficient mice (41). This strongly suggests that the protective effect provided by *Lactobacillus* is strain-specific. Importantly, nasal administration of *Lactobacillus* may activate PRRs by multiple pathways. Even if one PRR is blocked, another pathway can be activated to provide protection in a compensatory manner. For example, studies have shown that only when both NOD2 and TLR2 are knocked out can *L. plantarum* BAA-793 lose its role in protecting pneumonia virus infection (3, 64, 171). Therefore, components of *Lactobacillus* to activate the PRRs may be an important part of the protective role performed by intranasal *Lactobacillus* delivery.

The second one is that *Lactobacillus* can bind to host cells to antagonize adhesion or binding of pathogen. For the bacteria, experiments have demonstrated the ability of *Lactobacillus* to directly inhibit the adhesion of bacteria to respiratory epithelial cells. *L. rhamnosus* Kx151A1, *L. reuteri* PTA-5289, and *L. salivarius* LMG9477 can inhibit the adhesion of *S. pyogenes* to pharyngeal epithelial cells (172). Moreover, intranasal administration of *L. murinus* CNCM I-5314, a eubacterium of the murine lung, can provide a barrier function against the colonization of *S. pneumoniae* in the lung tissue (173). In the case of viruses, *Lactobacillus* binds competitively to viral receptor molecule to prevent viral entry into the host cell. For instance, lipopeptides released by *L. curvatus*, *L. sakei* and *L. lactis* (strains not shown) can bind to the receptor molecule (angiotensin-converting enzyme 2) of SARS-CoV-2 spike glycoprotein, and may prevent virus entry into host cells (174, 175). In addition to inhibiting the adhesion and binding of pathogenic bacteria, *Lactobacillus* directly displays antibacterial activity. Some *Lactobacillus* spp. exhibit antibacterial effect against group A *Streptococcus* in vitro (176). Similarly, *L. rhamnosus* Kx151A1 and *L. reuteri* PTA-5289 significantly inhibit hemolytic activity of *S. pyogenes* in vitro (172). Additionally, some proteins secreted by *Lactobacillus* have antimicrobial activity. For example, reuterin secreted by *L. reuteri* has broad-spectrum antibacterial effect (2). However, whether it will alter lung microbial composition and affect lung homeostasis remains further investigation.

### 4 SAFETY

As normal members of the human intestinal, vaginal, skin, oral and respiratory flora, *Lactobacillus* are low-toxicity commensal organisms and are mostly considered safe when taken as probiotics. In animal studies, long-term oral administration of *L. plantarum* PS128 had no bad side on the health in mice (177). In addition, nasal inoculation of *L. reuteri* F275 and *L. rhamnosus* GG, which are generally colonized in the intestinal tract. *L. reuteri* F275 is cleared in lung tissue less than 24 hours (178); live *L. rhamnosus* GG is detected on the nasal mucosa at 24 hours after intranasal administration, but not after 72 hours, and does not affect body weight or behavior in mice (97). In clinical trials, oral administration of some common *Lactobacillus* species such as *L. reuteri* DSM17938, *L. casei* Shirota and *L. salivarius*...
CECT5713 is safe in infants or children (2, 179–181). Moreover, with a long history of safe use, Lactobacilli are classified as GRAS (Generally Recognized as Safe) and QPS (Qualified Presumption of Safety) by the US Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA, 2021), respectively (182). Therefore, administration of some Lactobacillus species is generally safe.

However, when Lactobacillus is given intranasally, it can colonize the respiratory tract for long periods of time, and whether this could interfere lung microbial homeostasis or induce more severe inflammation or even lead to bacteremia is not clear. Although Lactobacillus bacteremia is a rare disease, it has been found in the clinical that L. rhamnosus GG and L. casei (strain not shown), which are generally considered safe, can also cause bacteremia when in a state of immunosuppression, prolonged hospitalization or surgical intervention (183). Even non-pathogenic bacteria of L. salivarius (strain not shown) in the oral cavity have been found to cause bacteremia, septic chest and diabetic ketoacidosis due to respiratory failure in the clinical (184). Moreover, it has been reported that pneumonia and pleural abscess are caused by mixed Lactobacillus infection in elderly people with esophageal cancer (185). Although it occurs being rare and almost exclusively in infants, children and immune-compromised populations, this also suggests that live Lactobacillus is not absolutely safe, especially when administered intranasally. Further, the presence of antibiotic resistance genes and virulence genes in Lactobacillus and their possible transfer to other microorganisms is also a concern.

5 CONCLUDING REMARKS

The use of Lactobacillus is a promising strategy for the prevention and treatment of respiratory diseases and is generally safe. The mechanism of Lactobacillus in regulating respiratory immunity includes the gut-lung axis and activation of mucosal immunity. The beneficial role of Lactobacillus on the respiratory tract is strain-dependent, and may change in different species of Lactobacillus and even subspecies of each Lactobacillus (32). Therefore, for clinical applications, the selection of effective Lactobacillus strains is crucial. Additionally, a single Lactobacillus is not always effective for all respiratory diseases and efficacy may be inconsistent even if the same Lactobacillus is administered due to many factors such as subject, dose and time of administration in clinical trials. The uncertainty of the effectiveness of Lactobacillus is one of the main reasons limiting their application in the clinic. For this problem, co-administration of multiple probiotic Lactobacillus or co-administration of probiotic Lactobacillus and other probiotics such as Bifidobacterium can provide more stable and better efficacy, which is also the trend of probiotic application. Furthermore, clinical application of the main active ingredients of Lactobacillus or inactivated bacteria can provide more safer effect and stable efficacy relative to live bacteria. Besides, Lactobacillus has preventive effect for offspring respiratory disease when administered to the mother, and it can greatly reduce the occurrence and alleviate the symptoms of respiratory diseases in infants and children if the stability and safety of Lactobacillus efficacy is fully established. Additionally, the economic burden of clinical application of Lactobacillus is low (186). Overall, administration of Lactobacillus is beneficial in improving pulmonary health and its application in treating respiratory diseases needs more clinical studies.

AUTHOR CONTRIBUTIONS

TD finished the original manuscript. NZ compiled table information. CZ and AL provided constructive comments and made critical revisions to the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

CZ was supported by National Natural Science Foundation of China (No. 31970177); AL was supported by the National Natural Science Foundation of Hunan Province (No. 2021JJ40475).

REFERENCES

1. Williams NT. Probiotics. Am J Health Syst Pharm (2010) 67(6):449–58. doi: 10.2146/ajhp090168
2. Mu Q, Tavella VJ, Luo XM. Role of Lactobacillus Reuteri in Human Health and Diseases. Front Microbiol (2018) 9:757. doi: 10.3389/fmicb.2018.00757
3. Gabryszewski SJ, Bachar O, Dyer KD, Percopo CM, Killoran KE, Domachowske JB, et al. Lactobacillus-Mediated Priming of the Respiratory Mucosa Protects Against Lethal Pneumovirus Infection. J Immunol (2011) 186(2):1151–61. doi: 10.4049/jimmunol.1001751
4. Duer RM, Lin XB, Zheng J, Martino ME, Grenier T, Perez-Munoz ME, et al. Lifestyles in Transition: Evolution and Natural History of the Genus Lactobacillus. FEMS Microbiol Rev (2017) 41(Suppl.1):527–48. doi: 10.1093/femsre/fux030
5. Goldstein EJ, Tyrell KL, Citron DM. Lactobacillus Species: Taxonomic Complexity and Controversial Susceptibilities. Clin Infect Dis (2015) 60 (Suppl 2):S98–107. doi: 10.1093/cid/civ072
6. Zhang Z, Lv J, Pan L, Zhang Y. Roles and Applications of Probiotic Lactobacillus Strains. Appl Microbiol Biotechnol (2018) 102(19):8135–43. doi: 10.1007/s00253-018-9217-9
7. O’Callaghan J, O’Toole PW. Lactobacillus: Host-Microbe Relationships. Curr Top Microbiol Immunol (2013) 358:119–54. doi: 10.1007/82_2011_187
8. Heeney DD, Gareau MG, Marco ML. Intestinal Lactobacillus in Health and Disease, a Driver or Just Along for the Ride? Curr Opin Biotechnol (2018) 49:140–7. doi: 10.1016/j.copbio.2017.08.004
9. Hojsak I. Probiotics in Functional Gastrointestinal Disorders. Adv Exp Med Biol (2019) 1125:121–37. doi: 10.1007/5584_2018_321
10. Margiotta G, Ferretti S, Graglia B, Gatto A, Capossela L, Bersani G, et al. Effect of Lactobacillus Reuteri Lr602-Lactobacillus Rhamnosus Lr04 Combination and Gastrointestinal Functional Disorders in an Emergency Department Pediatric Population. Eur Rev Med Pharmacol Sci (2021) 25(7):3097–104. doi: 10.26355/eurrev_202104_25564
44. Racedo S, Viliena J, Medina M, Aguerro G, Rodriguez V, Alvarez S. Lactobacillus Casei Administration Reduces Lung Injuries in a Streptococcus Pneumoniae Infection in Mice. *Microbes Infect* (2006) 8(10–11):2359–66. doi: 10.1016/j.micinf.2006.04.022.

45. Khailova L, Baird CH, Rush AA, McMannie EN, Wischmeyer PE. Lactobacillus Rhamnosus Gg Improves Outcome in Experimental Pseudomonas Aeruginosa Pneumonia: Potential Role of Regulatory T Cells. *Shock* (2013) 40(6):496–503. doi: 10.1097/SHK.0b013e31828fa2d9.

46. Alvarez S, Herrero C, Bui E, Perdigon G. Effect of Lactobacillus Casei and Yogurt Administration on Prevention of Pseudomonas Aeruginosa Infection in Young Mice. *J Food Prot* (2001) 64(11):1768–74. doi: 10.4318/jfpr.2001.64.11.1768.

47. Vareille-Delarbre M, Miguel S, Garcín S, Bertran T, Balestrino D, Eivard B, et al. Immunomodulatory Effects of Lactobacillus Plantarum on Inflammatory Response Induced by Klebsiella Pneumoniae. *Infect Immun* (2019) 87(11):00570-19. doi: 10.1128/IAI.00570-19.

48. Bernard-Raichon L, Colom A, Monard SC, Namouchi A, Cescato M, Youn HN, Lee DH, Lee YN, Park JK, Yuk SS, Yang SY, et al. Intranasal Administration of Lactobacillus Gasseri Sbt2055 Is Effective for Preventing *Pseudomonas aeruginosa* Infection in Mice. *Antiviral Res* (2015) 119:201–11. doi: 10.1016/j.antiviral.2015.07.001.

49. Clua P, Kanmani P, Zelaya H, Toda A, Kober AKMH, Salva S, et al. Peptidoglycan From Immunobiotic Lactobacillus Rhamnosus Improves Resistance of Infant Mice to Respiratory Syncytial Virus Infection and Secondary Pneumococcal Pneumonia. *Front Immunol* (2017) 8:948. doi: 10.3389/fimmu.2017.00948.

50. Clua P, Tomokiyo M, Vizoso-Pinto MG, Marcial G, et al. The Role of Alveolar Macrophages in the Improved Protection Against Respiratory Syncytial Virus and Pneumococcal Superinfection Induced by the Peptidoglycan of Lactobacillus Rhamnosus Cr1505. *Cells* (2020) 9(7):1653. doi: 10.3390/cells9071653.

51. Luoto R, Ruuskanen O, Waris M, Kalliomaki M, Salminen S, Isolauri E. Prebiotic and Probiotic Supplementation Prevents Rhinovirus Infections in Preterm Infants: A Randomized, Placebo-Controlled Trial. *J Allergy Clin Immunol* (2014) 133(2):405–13. doi: 10.1016/j.jaci.2013.08.020.

52. Vaisberg M, Paixao V, Almeida EB, Santos JMB, Foster R, Rossi M, et al. Daily Intake of Fermented Milk Containing Lactobacillus Casei Shirota (Lcs) Modulates Systemic and Upper Airways Immune/Inflammatory Responses in Marathon Runners. *Nutrients* (2019) 11(7):1678. doi: 10.3390/nu11071678.

53. Sanz JC, Mateos J, Conejo AM. Effect of Lactobacillus Casei on the Incidence of Infectious Conditions in Children. *Nutrición hospitalaria* (2006) 21(4):547–51.

54. Weizman Z, Asli G, Alsheikh A. Effect of a Probiotic Infant Formula on Infections in Child Care Centers: Comparison of Two Probiotic Agents. *Pediatrics* (2005) 115(1):5–9. doi: 10.1542/peds.2004-1815.

55. Bousquet J, Anto JM, Czarlewski W, Haahtela T, Fonseca SC, Iaccarino G, Bousquet JP, et al. Maternal Gut Microbiome Regulates Immunity to RSV Infection in Preterm Infants: A Randomized, Placebo-Controlled Trial. *Eur J Nutr* (2017) 56(1):46–55. doi: 10.1007/s00394-016-1573-1.

56. Islam MA, Albarracin L, Tomokiyo M, Valdez JC, Sacur J, Vizoso-Pinto MG, et al. Immunobiotic Lactobacillus Improves Resistance of Respiratory Epithelial Cells to Sars-Cov-2 Infection. *Pathogens* (2021) 10(9):1197. doi: 10.3390/pathogens10091197.

57. Maldonado J, Canabate F, Sempere L, Vela F, Sanchez AR, Narbona E, et al. Orally Administered Heat-Killed Lactobacillus Paracasei Mcc1849 Enhances Antigen-Specific Iga Secretion and Induces Folicular Helper T Cells in Mice. *PloS One* (2018) 13(6):e0199018. doi: 10.1371/journal.pone.0199018.

58. Nakayama Y, Moriya T, Sakai F, Ikeda N, Shiono K, Hosoya T, et al. Oral Administration of Lactobacillus Gasseri Sb2055 Is Effective for Preventing Influenza in Mice. *Sci Rep* (2014) 4:4638. doi: 10.1038/srep04638.

59. Asama T, Uematsu T, Kobayashi N, Tatefugi T, Hashimoto K, Oral Administration of Heat-Killed Lactobacillus Kunkei Yh38 Improves Murine Influenza Pneumonia by Enhancing Iga Production. *Bioscience microbiota Food Health* (2017) 36(1):1–9. doi: 10.12938/bmhf.16-010.

60. Fonolla J, Gracian C, Maldonado-Lobon JA, Romero C, Bedmar A, Carrillo JC, et al. Effects of Lactobacillus Coryniformis K8 Cec5711 on the Immune Response to Influenza Vaccination and the Assessment of Common Respiratory Symptoms in Elderly Subjects: A Randomized Controlled Trial. *Eur J Nutr* (2019) 58(1):83–90. doi: 10.1007/s00394-017-1573-1.

61. Yang WT, Yang GL, Yang X, Shonyela SM, Zhao L, Jiang YL, et al. Recombinant Lactobacillus Plantarum Expressing Ha2 Antigen Elicits Protective Immunity Against H9N2 Avian Influenza Virus in Chickens. *Appl Microbiol Biotechnol* (2017) 101(23-24):8475–84. doi: 10.1007/s00253-017-8600-2.

62. Peiroten A, Landete JM. Natural and Engineered Promoters for Gene Expression in Lactobacillus Species. *Appl Microbiol Biotechnol* (2020) 104(9):3797–805. doi: 10.1007/s00253-020-10426-0.

63. Fonseca WA, Malinzack CA, Fujimura K, Li D, McCauley K, Li J, et al. Maternal Gut Microbiome Regulates Immunity to Rsv Infection in Offspring. *J Exp Med* (2021) 218(11):e20210235. doi: 10.1084/jem.20210235.

64. Tao K, Tsou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The Biological and Clinical Significance of Emerging Sars-CoV-2 Variants. *Nat Rev Genet* (2021) 22(12):757–73. doi: 10.1038/s41576-021-00408-x.

65. Soloveva JV, Ilyicheva TN, Marchenko VY, Pyankov OV, Toshchina AG, Belova IV, et al. Genome Features and in Vitro Activity Against Influenza a and Sars-Cov-2 Viruses of Six Probiotic Strains. *Biosci Res* (2021) 2021:6662027. doi: 10.1155/2021/6662027.

66. Islam MA, Albarracin L, Tomokiyo M, Valdez JC, Sacur J, Vizoso-Pinto MG, et al. Immunobiotic Lactobacillus Improves Resistance of Respiratory Epithelial Cells to Sars-Cov-2 Infection. *Pathogens* (2021) 10(9):1197. doi: 10.3390/pathogens10091197.
119. Liu X, Cheng Y, Zang D, Zhang M, Li X, Liu D, et al. The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy. Front Oncol (2021) 11:720842. doi: 10.3389/fonc.2021.720842

120. Sivan A, Corrales L, Hubert N, Williams JB, Keston A M, Earley ZM, et al. Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. Science (2015) 27(350):1084–9. doi: 10.1126/science.aac4255

121. Yang JJ, Yu D, Xiang YB, Blot W, White E, Robien K, et al. Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk: A Pooled Analysis. JAMA Oncol (2020) 6(2):e194107. doi: 10.1001/jamaoncol.2019.4107

122. Bruzzese E, Raia V, Spagnuolo MI, Volpicelli M, De Marco G, Maiuri L, et al. Anti-Tumour Activity of Lactobacillus Rhamnosus CR15305 Prevents Inflammatory Response in the Respiratory Tract. Saudi J Biol Sci (2021) 28(10):5684–92. doi: 10.1016/j.sjbs.2021.06.010

123. Mortaz E, Adcock IM, Folkerts G, Barnes PJ, Paul Vos A, Garssen J. Probiotics in the Management of Lung Diseases. Mediators Inflamm (2013) 2013:751068. doi: 10.1153/2013/751068

124. Mortaz E, Adcock IM, Ricciardolo FL, Varahram M, Jamaati H, Velayati AA, Salva S, Gerez CL. Inorganic Polyphosphate From the Immunnobiotic Lactobacillus Rhamnosus GG Induces Proliferation of B-lymphocytes and Cytotoxic Activity. Cells (2020) 9:3767. doi: 10.3390/cells9063767

125. Mortaz E, Adcock IM, Folkerts G, Barnes PJ, Paul Vos A, Garssen J. Probiotics in the Management of Lung Diseases. Mediators Inflamm (2013) 2013:751068. doi: 10.1153/2013/751068

126. Wang Z, Li Y, Jia B, Li M, Yang X, Zhang Y, et al. Protection Against Asthmatic Mice by Lactobacillus Rhamnosus GG. Front Immunol (2021) 12:635471. doi: 10.3389/fimmu.2021.635471

127. Han W, Tang C, Baba S, Hamada T, Shimazu T, Iwakura Y. Oral Maintenance Therapy with Lactobacillus Rhamnosus GC009 in Chronic Obstructive Pulmonary Disease. Cell Immunol (2021) 350:107733. doi: 10.1016/j.cellimm.2021.107733

128. Jafari S-A, Atieh M-H, Kianifar H-R, Hebrani P, Ahanchian H, Abbasnejad D, et al. The Role of Lactobacillus Rhamnosus in Reducing Proinflammatory Cytokines in Type 2 Diabetes Mellitus. PLoS One (2015) 10(8):e0136455. doi: 10.1371/journal.pone.0136455

129. Li L, Fang Z, Lee YK, Zhao J, Zhang H, Lu W, et al. Prophylactic Effects of Probiotics in Children With Cystic Fibrosis: A Pilot Study. Cell Immunol (2016) 308:102–7. doi: 10.1016/j.cellimm.2016.06.010

130. Liu X, Cheng Y, Zang D, Zhang M, Li X, Liu D, et al. The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy. Front Oncol (2021) 11:720842. doi: 10.3389/fonc.2021.720842

131. Nishikawa T, Kato H, Watanabe Y, Ohmori Y, Onouchi H, Fujita Y, et al. Lactobacillus Rhamnosus GG Induced Lymphokine Production in Nasal Mucosa Cells From Asthmatic Patients. J Cyst Fibros (2017) 16(6):556–63. doi: 10.1016/j.jcf.2017.03.004

132. Kaczmarska ME, Kowalczyk K, Krzyzosiak M, Ciepluch M, Krzyzosiak W. Effect of Lactobacillus Rhamnosus GG on the Expression of Immune Parameters in Children With Cystic Fibrosis. Cell Immunol (2017) 322:18–27. doi: 10.1016/j.cellimm.2017.01.004

133. Liu X, Cheng Y, Zang D, Zhang M, Li X, Liu D, et al. The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy. Front Oncol (2021) 11:720842. doi: 10.3389/fonc.2021.720842

134. Mortaz E, Adcock IM, Folkerts G, Barnes PJ, Paul Vos A, Garssen J. Probiotics in the Management of Lung Diseases. Mediators Inflamm (2013) 2013:751068. doi: 10.1153/2013/751068

135. Gray J, Oehrle K, Worthen G, Alenghat T, Shelmukh J, Intestinal Commensal Bacteria Mediate Lung Mucosal Immunity and Promote Resistance of Newborn Mice to Infection. Sci Transl Med (2017) 9(376):eaaf9412. doi: 10.1126/scitranslmed.aaf9412

136. Zhang J, Ma JY, Li QH, Su H, Sun X. Lactobacillus Rhamnosus GG Induced Protective Effect on Allergic Airway Inflammation Is Associated With Gut Microbiota. Cell Immunol (2018) 332:77–84. doi: 10.1016/j.cellimm.2018.08.002

137. Han W, Tang C, Baba S, Hamada T, Shimazu T, Iwakura Y. Oral Maintenance Therapy with Lactobacillus Rhamnosus GC009 in Chronic Obstructive Pulmonary Disease. Cell Immunol (2021) 350:107733. doi: 10.1016/j.cellimm.2021.107733

138. Kaczmarska ME, Kowalczyk K, Krzyzosiak M, Ciepluch M, Krzyzosiak W. Effect of Lactobacillus Rhamnosus GG on the Expression of Immune Parameters in Children With Cystic Fibrosis. Cell Immunol (2017) 322:18–27. doi: 10.1016/j.cellimm.2017.01.004

139. Kaczmarska ME, Kowalczyk K, Krzyzosiak M, Ciepluch M, Krzyzosiak W. Effect of Lactobacillus Rhamnosus GG on the Expression of Immune Parameters in Children With Cystic Fibrosis. Cell Immunol (2017) 322:18–27. doi: 10.1016/j.cellimm.2017.01.004
179. Saviano A, Brigida M, Migneco A, Gunawardena G, Zanza C, Candelli M, et al. Lactobacillus Reuteri DSM 17938 (Limosilactobacillus Reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin? *Medicina (Kaunas)* (2021) 57(7):643. doi: 10.3390/medicina57070643

180. Maldonado J, Lara-Villoslada F, Sierra S, Sempere L, Gomez M, Rodriguez JM, et al. Safety and Tolerance of the Human Milk Probiotic Strain Lactobacillus Salivarius Cect5713 in 6-Month-Old Children. *Nutrition* (2010) 26(11-12):1082–7. doi: 10.1016/j.nut.2009.08.023

181. Guo C, Lei M, Wang Y, Hua L, Xue S, Yu D, et al. Oral Administration of Probiotic Lactobacillus Casei Shiota Decreases Pneumonia and Increases Pulmonary Functions After Single Rib Fracture: A Randomized Double-Blind, Placebo-Controlled Clinical Trial. *J Food Sci* (2018) 83(8):2222–6. doi: 10.1111/1750-3841.14220

182. Colautti A, Arnoldi M, Comi G, Iacumin L. Antibiotic Resistance and Virulence Factors in Lactobacilli: Something to Carefully Consider. *Food Microbiol* (2022) 103:103934. doi: 10.1016/j.fm.2021.103934

183. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus Bacteremia, Clinical Significance, and Patient Outcome, With Special Focus on Probiotic L. Rhamnosus Gg. *Clin Infect Dis* (2004) 38 (1):62–9. doi: 10.1086/380455

184. Wang H-K, Teng L-J, Chen Y-C, Du S-H, Hsueh P-R. Lactobacillus Salivarius Emphyema With Respiratory Failure. *J Microbiol Immunol Infect* (2017) 50(6):923–5. doi: 10.1016/j.jmii.2016.06.001

185. Chaini E, Chainis ND, Ioannidis A, Magana M, Nikolau C, Papparaskevas J, et al. Pneumonia and Pleural Emphyema Due to a Mixed Lactobacillus Spp. Infection as a Possible Early Esophageal Carcinoma Signature. *Front Med (Lausanne)* (2016) 3:42. doi: 10.3389/fmed.2016.00042

186. Zhang J, Bu Y, Zhang C, Yi H, Liu D, Jiao J. Development of a Low-Cost and High-Efficiency Culture Medium for Bacteriocin Lac B23 Production by Lactobacillus Plantarum J23. *Biol (Basel)* (2020) 9(7):171. doi: 10.3390/biology9070171

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Du, Lei, Zhang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.